Trials / Recruiting
RecruitingNCT05630235
Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI
Effects of a Hemp-derived Cannabidiol and Cannabidiolic-acid Oral Extract on Resting-state Electroencephalography and Neuropathic Pain Symptoms in People With Spinal Cord Injury
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- University of Miami · Academic / Other
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The main purposes of this study are to (1) measure the effect of CBD/CBD-A on pain symptoms, pain intensity, pain unpleasantness, and skin sensitivity to hot and cold temperatures; and (2) measure the effect of CBD on brain electrical activity with electroencephalography (EEG).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CBD/CBD-A | Participants will be administered a one-time dose of 204.6 mg of CBD/CBD-A orally. |
| OTHER | Placebo | The placebo equivalent of the CBD/CBD-A dose administered orally. |
Timeline
- Start date
- 2025-06-16
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2022-11-29
- Last updated
- 2025-06-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05630235. Inclusion in this directory is not an endorsement.